Toframicin; The next-generation antibiotic

The next-generation aminoglycoside antibiotic

Toframicin is a semi-synthetic antibiotic which is in development for the treatment of hospital-acquired-/ventilator-associated pneumonia, bloodstream infections and neonatal sepsis.

Toframicin has ultra-broad spectrum activity, overcome drug class-related bacterial resistance, and offers an increased therapeutic window.

Technology:
  • Antimicrobial compounds
  • Infection prevention
  • Antimicrobial stewardship
  • Microbial diagnostics
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

Microorganisms:
  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

Application:
  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Development
  • Research
  • Validation
  • Market entry
  • Marketed product

Organization:
  • Company
  • Academia
  • Institute
  • NGO
  • Government

Partnering:
  • License
  • Co-develop
  • Outsource
  • Joint Venture
  • Sell

Funding organisation: WordPress › Error

There has been a critical error on this website.

Learn more about troubleshooting WordPress.